- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07225946
Pasritamigin ja doksatakselin yhdistelmän tutkimus verrattuna pelkkään doksatakseliin etäpesäkkeiseen kastraatio-resistentissä eturauhassyövässä sairastavilla osallistujilla (KLK2-PASenger)
Kohdistettu vaihe 3 -satunnaistettu, avoimen merkinnän tutkimus pasritamigista (JNJ-78278343), T-solu-uudelleenohjaavasta aineesta, joka kohdistuu ihmisen kallikreiini 2:een, doksatakselin kanssa verrattuna doksatakseliin etäpesäkkeisessä kastraatio-resistentissä eturauhassyövässä
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or death due to any cause) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Study Contact
- Puhelinnumero: 844-434-4210
- Sähköposti: Participate-In-This-Study1@its.jnj.com
Opiskelupaikat
-
-
-
Heidelberg, Australia, 3084
- Rekrytointi
- Warringal Private Hospital
-
Kurralta Park, Australia, 5037
- Rekrytointi
- Icon Cancer Centre Kurralta Park
-
Melbourne, Australia, 3000
- Rekrytointi
- Peter MacCallum Cancer Centre
-
Wahroonga, Australia, 2076
- Rekrytointi
- Sydney Adventist Hospital
-
Woolloongabba, Australia, 4102
- Rekrytointi
- Princess Alexandra Hospital
-
-
-
-
-
Aalst, Belgia, 9300
- Rekrytointi
- AZORG campus Aalst Moorselbaan
-
Antwerp, Belgia, 2610
- Rekrytointi
- ZAS Augustinus
-
Ghent, Belgia, 9000
- Rekrytointi
- AZ Maria Middelares
-
La Louvière, Belgia, 7100
- Rekrytointi
- Chu Helora Hospital La Louviere Site Jolimont
-
Liège, Belgia, 4000
- Rekrytointi
- CHC MontLegia
-
-
-
-
-
Bauru, Brasilia, 17033-495
- Rekrytointi
- NAIC Nair Antunes Instituto do Cancer
-
Natal, Brasilia, 59062 000
- Rekrytointi
- Liga Norte Riograndense Contra O Cancer
-
Santa Cruz do Sul, Brasilia, 96835-100
- Rekrytointi
- Hospital Ana Nery Santa Cruz do Sul
-
Santo André, Brasilia, 09060 870
- Rekrytointi
- CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
-
São Paulo, Brasilia, 01243 020
- Rekrytointi
- Hospital Samaritano de Sao Paulo
-
-
-
-
-
Badalona, Espanja, 08916
- Rekrytointi
- Hosp. Univ. Germans Trias I Pujol
-
Madrid, Espanja, 28034
- Rekrytointi
- Hosp. Univ. Ramon Y Cajal
-
Madrid, Espanja, 28041
- Rekrytointi
- Hosp. Univ. 12 de Octubre
-
Murcia, Espanja, 30008
- Rekrytointi
- Hosp. Gral. Univ. J.M. Morales Meseguer
-
Seville, Espanja, 41009
- Rekrytointi
- Hosp. Virgen Macarena
-
Valencia, Espanja, 46014
- Rekrytointi
- Hosp. Gral. Univ. Valencia
-
Zaragoza, Espanja, 50009
- Rekrytointi
- Hosp. Clinico Univ. Lozano Blesa
-
-
-
-
-
Goyang-si, Etelä -Korea, 10408
- Rekrytointi
- National Cancer Center
-
Seoul, Etelä -Korea, 05505
- Rekrytointi
- Asan Medical Center
-
Seoul, Etelä -Korea, 06351
- Rekrytointi
- Samsung Medical Center
-
Seoul, Etelä -Korea, 03722
- Rekrytointi
- Severance Hospital Yonsei University Health System
-
Seoul, Etelä -Korea, 06591
- Rekrytointi
- The Catholic University of Korea Seoul St Marys Hospital
-
-
-
-
-
Florence, Italia, 50134
- Rekrytointi
- Azienda Ospedaliero Universitaria Careggi
-
Localita La Schiana Pozzuoli, Italia, 80078
- Rekrytointi
- ASL Napoli 2 Nord-SM delle Grazie Hospital
-
Milan, Italia, 20141
- Rekrytointi
- Istituto Europeo di Oncologia
-
Milan, Italia, 20132
- Rekrytointi
- IRCCS Ospedale San Raffaele
-
Roma, Italia, 00144
- Rekrytointi
- Istituto Nazionale Tumori Regina Elena
-
Torino, Italia, 10126
- Rekrytointi
- Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino
-
-
-
-
-
Bunkyō City, Japani, 113 8431
- Rekrytointi
- Juntendo University Hospital
-
Hirakata, Japani, 573-1191
- Rekrytointi
- Kansai Medical University Hospital
-
Kanazawa, Japani, 920 8641
- Rekrytointi
- Kanazawa University Hospital
-
Kobe, Japani, 650 0017
- Rekrytointi
- Kobe University Hospital
-
Sagamihara, Japani, 252-0375
- Rekrytointi
- Kitasato University Hospital
-
Sunto Gun, Japani, 411 8777
- Rekrytointi
- Shizuoka Cancer Center
-
Yokohama, Japani, 232 0024
- Rekrytointi
- Yokohama City University Medical Center
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z4E6
- Rekrytointi
- British Columbia Cancer Agency
-
Victoria, British Columbia, Kanada, V8R 6V5
- Rekrytointi
- British Columbia Cancer Agency Vancouver Island Centre
-
-
Ontario
-
Ottawa, Ontario, Kanada, K1H 8L6
- Rekrytointi
- The Ottawa Hospital Cancer Centre
-
Toronto, Ontario, Kanada, M5G 2C4
- Rekrytointi
- Princess Margaret Cancer Centre
-
-
Quebec
-
Montreal, Quebec, Kanada, H2X 0A9
- Rekrytointi
- Centre de Recherche du CHUM
-
Québec, Quebec, Kanada, G1R 2J6
- Rekrytointi
- CHU de Quebec Universite Laval
-
-
-
-
-
Beijing, Kiina, 100142
- Rekrytointi
- Beijing Cancer Hospital
-
Beijing, Kiina, 100034
- Rekrytointi
- Peking University First Hospital
-
Beijing, Kiina, 101100
- Rekrytointi
- Beijing Luhe Hospital, Capital Medical University
-
Chengdu, Kiina, 610014
- Rekrytointi
- The Third People's Hospital of Chengdu
-
Chengdu, Kiina, 610041
- Rekrytointi
- West China Hospital Sichuan University
-
Chongqing, Kiina, 400030
- Rekrytointi
- Chongqing University Cancer Hospital
-
Guangzhou, Kiina, 510120
- Rekrytointi
- The First Affiliated Hospital of Guangzhou Medical University
-
Guangzhou, Kiina, 510060
- Rekrytointi
- Sun Yat Sen University Cancer Center
-
Hangzhou, Kiina, 310009
- Rekrytointi
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Nanjing, Kiina, 210009
- Rekrytointi
- Nanjing Drum Tower Hospital
-
Shanghai, Kiina, 200080
- Rekrytointi
- Shanghai General Hospital
-
Shanghai, Kiina, 200031
- Rekrytointi
- Huashan Hospital Fudan University
-
Shanghai, Kiina, 200082
- Rekrytointi
- Xinhua hospital,Shanghai Jiaotong University
-
Tianjin, Kiina, 300211
- Rekrytointi
- The Second Hospital Of Tianjin Medical University
-
Wuhan, Kiina, 430014
- Rekrytointi
- The Central Hospital of Wuhan
-
Xi'an, Kiina, 710061
- Rekrytointi
- The First Affiliated Hospital of Xian Jiaotong University
-
-
-
-
-
Kota Kinabalu, Malesia, 88996
- Rekrytointi
- Hospital Wanita dan Kanak-Kanak Sabah
-
Kuala Lumpur, Malesia, 59100
- Rekrytointi
- University Malaya Medical Centre
-
Kuala Lumpur, Malesia, 50586
- Rekrytointi
- Hospital Kuala Lumpur
-
Kuala Lumpur, Malesia, 59100
- Rekrytointi
- Pantai Hospital Kuala Lumpur
-
Kuching, Malesia, 93586
- Rekrytointi
- Hospital Umum Sarawak
-
-
-
-
-
San Juan, Puerto Rico, 935
- Rekrytointi
- Pan American Center for Oncology Trials LLC
-
-
-
-
-
Bordeaux, Ranska, 33076
- Rekrytointi
- Institut Bergonie
-
Clermont-Ferrand, Ranska, 63011
- Rekrytointi
- Centre Jean Perrin
-
Lille, Ranska, 59000
- Rekrytointi
- Centre Oscar Lambret
-
Lyon, Ranska, 69008
- Rekrytointi
- Centre Leon Berard
-
Nîmes, Ranska, 30900
- Rekrytointi
- Groupe Hospitalo-Universitaire Carémeau
-
Paris, Ranska, 75908
- Rekrytointi
- Hopital Europeen Georges-Pompidou
-
Rennes, Ranska, 35062
- Rekrytointi
- Centre Eugene Marquis
-
Villejuif, Ranska, 94800
- Rekrytointi
- Gustave Roussy
-
-
-
-
-
Dresden, Saksa, 01307
- Rekrytointi
- Universitatsklinikum Carl Gustav Carus Dresden
-
Duisburg, Saksa, 47169
- Rekrytointi
- Urologicum Duisburg
-
Essen, Saksa, 45147
- Rekrytointi
- Universitaetsklinikum Essen
-
Hamburg, Saksa, 20246
- Rekrytointi
- Martini-Klinik am Universitätsklinikum Hamburg-Eppendorf Urologie
-
München, Saksa, 81675
- Rekrytointi
- Klinikum rechts der Isar an der Technischen Universitat Munchen
-
Nürtingen, Saksa, 72622
- Rekrytointi
- Studienpraxis Urologie Drs. Feyerabend
-
-
-
-
-
Taichung, Taiwan, 435
- Rekrytointi
- Tungs' Taichung MetroHarbor Hospital
-
Taichung, Taiwan, 404
- Rekrytointi
- China Medical University Hospital
-
Taichung, Taiwan, 407219
- Rekrytointi
- Taichung Veterans General Hospital
-
Tainan, Taiwan, 704
- Rekrytointi
- National Cheng Kung University Hospital
-
Taoyuan, Taiwan, 333
- Rekrytointi
- Linkou Chang Gung Memorial Hospital
-
-
-
-
-
Adana, Turkki (Türkiye), 01170
- Rekrytointi
- Adana City Hospital
-
Ankara, Turkki (Türkiye), 06010
- Rekrytointi
- Gulhane Training and Research Hospital
-
Ankara, Turkki (Türkiye), 06100
- Rekrytointi
- Ankara University Medical Faculty
-
Istanbul, Turkki (Türkiye), 34096
- Rekrytointi
- Istanbul University Cerrahpasa tip Fakultesi
-
Istanbul, Turkki (Türkiye), 34147
- Rekrytointi
- Koc Universitesi Hastanesi
-
Izmir, Turkki (Türkiye), 35170
- Rekrytointi
- Medicana International Izmir
-
-
-
-
-
Cardiff, Yhdistynyt kuningaskunta, CF14 2TL
- Rekrytointi
- Velindre Cancer Centre
-
Glasgow, Yhdistynyt kuningaskunta, G12 0YN
- Rekrytointi
- Beatson West Of Scotland Cancer Centre
-
London, Yhdistynyt kuningaskunta, EC1A 7BE
- Rekrytointi
- St Bartholomews Hospital
-
London, Yhdistynyt kuningaskunta, SW3 6JJ
- Rekrytointi
- The Royal Marsden NHS Trust
-
Newcastle upon Tyne, Yhdistynyt kuningaskunta, NE7 7DN
- Rekrytointi
- The Newcastle upon Tyne Hospitals NHS Trust - Freeman Hospit
-
Preston, Yhdistynyt kuningaskunta, PR2 9HT
- Rekrytointi
- Lancashire Teaching Hospitals NHS Foundation Trust Royal Preston Hospital
-
Sutton, Yhdistynyt kuningaskunta, SM2 5PT
- Rekrytointi
- Royal Marsden Hospital
-
-
-
-
Arizona
-
Chandler, Arizona, Yhdysvallat, 85225
- Rekrytointi
- Arizona Clinical Trials
-
-
Arkansas
-
Little Rock, Arkansas, Yhdysvallat, 72211
- Rekrytointi
- Arkansas Urology
-
Springdale, Arkansas, Yhdysvallat, 72762
- Rekrytointi
- Highlands Oncology Group
-
-
California
-
Fountain Valley, California, Yhdysvallat, 92708
- Rekrytointi
- MemorialCare Orange Coast Medical Center
-
La Jolla, California, Yhdysvallat, 92037
- Rekrytointi
- University Of California San Diego
-
Los Alamitos, California, Yhdysvallat, 90720
- Rekrytointi
- Cancer and Blood Specialty Clinic
-
Los Angeles, California, Yhdysvallat, 90033
- Rekrytointi
- USC Norris Comprehensive Cancer Center
-
Los Angeles, California, Yhdysvallat, 90095
- Rekrytointi
- Ronald Reagan UCLA Medical Center
-
Los Angeles, California, Yhdysvallat, 90067
- Rekrytointi
- Valkyrie Clinical Trials
-
Riverside, California, Yhdysvallat, 92505
- Rekrytointi
- Kaiser Permanente Southern California
-
San Diego, California, Yhdysvallat, 92123
- Rekrytointi
- Sharp Center for Research
-
Santa Monica, California, Yhdysvallat, 90404
- Rekrytointi
- Providence Saint John s Health Center
-
-
Colorado
-
Aurora, Colorado, Yhdysvallat, 80012
- Rekrytointi
- Rocky Mountain Cancer Centers
-
Denver, Colorado, Yhdysvallat, 80210
- Rekrytointi
- AdventHealth Porter Oncology Research
-
Edwards, Colorado, Yhdysvallat, 81632
- Rekrytointi
- Vail Health Shaw Cancer Center
-
Grand Junction, Colorado, Yhdysvallat, 81505
- Rekrytointi
- Grand Valley Oncology
-
Lakewood, Colorado, Yhdysvallat, 80228
- Rekrytointi
- Colorado Clinical Research
-
-
Florida
-
Orlando, Florida, Yhdysvallat, 32803
- Rekrytointi
- AdventHealth Orlando
-
Pembroke Pines, Florida, Yhdysvallat, 33026
- Rekrytointi
- Memorial Cancer Institute
-
Sarasota, Florida, Yhdysvallat, 34232
- Rekrytointi
- Florida Cancer Specialists
-
-
Georgia
-
Atlanta, Georgia, Yhdysvallat, 30322
- Rekrytointi
- Winship Cancer Institute Emory University
-
-
Illinois
-
Lisle, Illinois, Yhdysvallat, 60532
- Rekrytointi
- Duly Health and Care
-
-
Kansas
-
Wichita, Kansas, Yhdysvallat, 67214
- Rekrytointi
- Cancer Center of Kansas Heritage Plaza Medical Building
-
-
Kentucky
-
Edgewood, Kentucky, Yhdysvallat, 41017
- Rekrytointi
- St Elizabeth Healthcare
-
Louisville, Kentucky, Yhdysvallat, 40207
- Rekrytointi
- Norton Cancer Institute
-
-
Louisiana
-
Metairie, Louisiana, Yhdysvallat, 70006
- Rekrytointi
- East Jefferson General Hospital
-
-
Maryland
-
Baltimore, Maryland, Yhdysvallat, 21287
- Rekrytointi
- Johns Hopkins Hospital
-
Baltimore, Maryland, Yhdysvallat, 21201
- Rekrytointi
- University of Maryland
-
Baltimore, Maryland, Yhdysvallat, 21287
- Rekrytointi
- Johns Hopkins Medical Institutions
-
Bethesda, Maryland, Yhdysvallat, 20817
- Rekrytointi
- Center for Cancer and Blood Disorders
-
Towson, Maryland, Yhdysvallat, 21204
- Rekrytointi
- Chesapeake Urology Research Associates
-
-
Massachusetts
-
Boston, Massachusetts, Yhdysvallat, 02114
- Rekrytointi
- Massachusetts General
-
-
Michigan
-
Sterling Heights, Michigan, Yhdysvallat, 48314
- Rekrytointi
- Profound Research LLC at Cancer and Leukemia Center
-
-
Minnesota
-
Saint Louis Park, Minnesota, Yhdysvallat, 55426
- Rekrytointi
- HealthPartners Frauenshuh Cancer Center CRC West
-
Saint Paul, Minnesota, Yhdysvallat, 55101
- Rekrytointi
- HealthPartners Cancer Center at Regions Hospital CRC East
-
-
Mississippi
-
Jackson, Mississippi, Yhdysvallat, 39216
- Rekrytointi
- University of Mississippi Medical Center
-
-
Missouri
-
St Louis, Missouri, Yhdysvallat, 63110
- Rekrytointi
- Washington University
-
-
Nebraska
-
Lincoln, Nebraska, Yhdysvallat, 68506
- Rekrytointi
- NHO Revive Research Institute, LLC
-
-
New Jersey
-
Camden, New Jersey, Yhdysvallat, 08103
- Rekrytointi
- Cooper Health System MD Anderson Cancer Center at Cooper
-
East Brunswick, New Jersey, Yhdysvallat, 08816
- Rekrytointi
- Astera Cancer Care
-
New Brunswick, New Jersey, Yhdysvallat, 08901
- Rekrytointi
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
Mineola, New York, Yhdysvallat, 11501
- Rekrytointi
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island
-
New York, New York, Yhdysvallat, 10016
- Rekrytointi
- NYU Langone Health Laura and Isaac Perlmutter Cancer Center
-
The Bronx, New York, Yhdysvallat, 10461
- Rekrytointi
- Montefiore Medical Center
-
-
North Carolina
-
Durham, North Carolina, Yhdysvallat, 27710
- Rekrytointi
- Duke University Medical Center
-
-
Ohio
-
Canton, Ohio, Yhdysvallat, 44718
- Rekrytointi
- Gabrail Cancer Center
-
Cincinnati, Ohio, Yhdysvallat, 45219
- Rekrytointi
- University of Cincinnati
-
Cleveland, Ohio, Yhdysvallat, 44109
- Rekrytointi
- Metrohealth Medical Center
-
-
Oregon
-
Springfield, Oregon, Yhdysvallat, 97477
- Rekrytointi
- Oregon Urology Institute
-
-
Pennsylvania
-
Allentown, Pennsylvania, Yhdysvallat, 18103
- Rekrytointi
- Lehigh Valley Hospital
-
Bala-Cynwyd, Pennsylvania, Yhdysvallat, 19004
- Rekrytointi
- MidLantic Urology
-
Hershey, Pennsylvania, Yhdysvallat, 17033
- Rekrytointi
- Penn State Milton S. Hershey Medical Center
-
Pittsburgh, Pennsylvania, Yhdysvallat, 15232
- Rekrytointi
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center
-
-
South Carolina
-
Myrtle Beach, South Carolina, Yhdysvallat, 29572
- Rekrytointi
- Carolina Urologic Research Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Yhdysvallat, 57105
- Rekrytointi
- Avera Medical Group
-
Watertown, South Dakota, Yhdysvallat, 57201
- Rekrytointi
- Prairie Lakes Health Care System
-
-
Tennessee
-
Knoxville, Tennessee, Yhdysvallat, 37909
- Rekrytointi
- Tennessee Cancer Specialists
-
-
Texas
-
Austin, Texas, Yhdysvallat, 78731
- Rekrytointi
- Texas Oncology
-
Dallas, Texas, Yhdysvallat, 75390
- Rekrytointi
- UT Southwestern Medical Center
-
Houston, Texas, Yhdysvallat, 77027
- Rekrytointi
- Houston Metro Urology
-
Sugar Land, Texas, Yhdysvallat, 77479
- Rekrytointi
- Texas Oncology 1
-
The Woodlands, Texas, Yhdysvallat, 77380
- Rekrytointi
- Renovatio Clinical
-
-
Virginia
-
Fairfax, Virginia, Yhdysvallat, 22031
- Rekrytointi
- Virginia Cancer Specialists
-
-
Washington
-
Seattle, Washington, Yhdysvallat, 98109
- Rekrytointi
- Fred Hutchinson Cancer Research Center
-
Seattle, Washington, Yhdysvallat, 98109
- Rekrytointi
- Fred Hutch Cancer Center Sloan Clinic 2
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion criteria:
- Have histologically confirmed adenocarcinoma of the prostate
- Have disease that is metastatic at the time of screening by computed tomography (CT) or magnetic resonance imaging (MRI) and 99m^Tc bone scan as determined by the investigator
- Participants must receive ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone (GnRH) analog throughout the treatment or have had prior bilateral orchiectomy, and have serum testosterone less than or equal to (<=) 50 nanogram per deciliter (ng/dL) (<= 1.73 nanomoles per Liter [nmol/L]) at screening
- Have progressed by PSA or CT/MRI or 99m^Tc bone scan on at least 1 novel androgen receptor pathway inhibition (ARPI) but no more than 2 different ARPI for any stage of disease. Must have discontinued ARPI before randomization into the study
- Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1
Exclusion criteria:
- Known history of either brain or leptomeningeal prostate cancer metastases
- Participants with known breast cancer gene 1/2 (BRCA 1/2) mutations (germline or somatic) who have not received treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor, unless not available or contraindicated
- Prior or concurrent second malignancy (other than the disease under study)
- Received cytotoxic chemotherapy for prostate cancer in any setting
- Received prior treatment with human kallikrein 2 (KLK-2) directed therapies
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Pasritamig+Docetaxel
Participants will receive pasritamig along with docetaxel until the end of treatment (EOT) visit or until radiographic disease progression is confirmed by blinded independent central review (BICR), or any other protocol defined criteria are met. |
Pasritamig will be administered.
Muut nimet:
Docetaxel will be administered. |
|
Active Comparator: Docetaxel
Participants will receive docetaxel along with prednisone/prednisolone as background medication. |
Docetaxel will be administered. Prednisone/Prednisolone will be administered. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Radiographic Progression-Free Survival (rPFS) by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan Assessed by Blinded Independent Central Review (BICR)
Aikaikkuna: Up to approximately 1 years 10 months
|
rPFS by CT/MRI or bone scan is assessed by BICR and is defined as the time from the date of randomization to the first date of radiographic disease progression, or death due to any cause, whichever occurs first. |
Up to approximately 1 years 10 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Overall Survival (OS)
Aikaikkuna: Up to approximately 4 years 5 months
|
OS is defined as the time from the date of randomization to the date of death due to any cause. |
Up to approximately 4 years 5 months
|
|
Time to Symptomatic Progression (TSP)
Aikaikkuna: Up to approximately 4 years 5 months
|
TSP is defined as the time from the date of randomization to the date of the first occurrence of any of the following: the use of external beam radiation to relieve cancer-related symptoms, the need for tumor-related surgical intervention, other cancer-related procedures, cancer-related morbid events, and initiation of a new systemic anticancer therapy because of cancer symptoms. |
Up to approximately 4 years 5 months
|
|
Time to Subsequent Therapy (TST)
Aikaikkuna: Up to approximately 4 years 5 months
|
TST is defined as time from randomization to the initiation of any subsequent systemic anticancer therapy for prostate cancer |
Up to approximately 4 years 5 months
|
|
Time to Skeletal-Related Event (TSRE)
Aikaikkuna: Up to approximately 4 years 5 months
|
TSRE is defined as the time from the date of randomization to the date of first occurrence of any of the following (whichever occurs first): the use of external beam radiation therapy to relieve skeletal symptoms, the need for tumor-related orthopedic surgical intervention, the occurrence of new bone fractures (cancer-related; vertebral or non-vertebral) or the occurrence of tumor-related spinal cord compression. |
Up to approximately 4 years 5 months
|
|
Objective Response Rate (ORR)
Aikaikkuna: Up to approximately 4 years 5 months
|
ORR is defined as the proportion of participants who have measurable disease at baseline and have complete response (CR) or partial response (PR) or better by objective radiographic disease evaluation per response evaluation criteria in solid tumors (RECIST) version.1.1 response criteria and no bone progression as per prostate cancer working group 3 (PCWG3) as determined by the BICR. |
Up to approximately 4 years 5 months
|
|
Duration of Response (DOR)
Aikaikkuna: Up to approximately 4 years 5 months
|
DOR will be calculated among responders (PR or better) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the PCWG3 or RECIST version 1.1 response criteria, or death due to any cause, whichever occurs first. |
Up to approximately 4 years 5 months
|
|
Time to Prostate-Specific Antigen (PSA) Progression
Aikaikkuna: Up to approximately 4 years 5 months
|
Time to PSA progression is defined as the time from randomization to the first date of documented PSA progression per prostate cancer working group 3 (PCWG3) criteria. PSA progression is defined as: (1) After a decline from baseline, PSA increases greater than or equal to (>=) 25% and >=2 nanogram per milliliter (ng/mL) above the nadir, confirmed by a second value >=3 weeks later (that is, a confirmed rising trend), or (2) If there is no decline from baseline, PSA increases >=25% and >=2 ng/mL from baseline after 12 weeks |
Up to approximately 4 years 5 months
|
|
Proportion of Participants Who Achieved Prostate-Specific Antigen (PSA) 50 Response
Aikaikkuna: Up to approximately 4 years 5 months
|
PSA-50 response is defined as the proportion of participants with a reduction in blood concentration of PSA (ng/mL) to 50% from baseline, confirmed by a second value, at least 3 weeks apart. |
Up to approximately 4 years 5 months
|
|
Proportion of Participants Who Achieved Prostate-Specific Antigen (PSA) 90 Response
Aikaikkuna: Up to approximately 4 years 5 months
|
PSA-90 response is defined as the proportion of participants with a reduction in blood concentration of PSA (ng/mL) to 90% from baseline, confirmed by a second value, at least 3 weeks apart. |
Up to approximately 4 years 5 months
|
|
Duration of PSA Response
Aikaikkuna: Baseline and up to approximately 4 years 5 months
|
Duration of a PSA response is the time taken to achieve a PSA response that is decrease in PSA from baseline by >= 50%. |
Baseline and up to approximately 4 years 5 months
|
|
Progression Free Survival After Subsequent Therapy (PFS2)
Aikaikkuna: Up to approximately 4 years 5 months
|
PFS2 is defined as the time from randomization to the date of progression (radiographic, clinical, or PSA progression) on the first subsequent anti-cancer (second progression), or death from any cause, whichever comes first. |
Up to approximately 4 years 5 months
|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) by Severity
Aikaikkuna: Up to approximately 4 years 5 months
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. An SAE: results in death, is life-threatening, requires inpatient hospitalization or prolonging hospitalization, results in disability, is a congenital birth defect, is a suspected transmission of any infectious agent via a medicinal product, is indicating suicidal ideation, is medically important. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. by using standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE. |
Up to approximately 4 years 5 months
|
|
Number of Participants With Clinical Laboratory Abnormalities
Aikaikkuna: Up to approximately 4 years 5 months
|
Participants with laboratory abnormalities (hematology, serum chemistry, coagulation, and tumor markers) will be reported. |
Up to approximately 4 years 5 months
|
|
Change from Baseline in Health Related Quality of Life (HRQoL) as Assessed by Brief Pain Inventory-Short Form (BPI-SF)
Aikaikkuna: Baseline up to approximately 4 years 5 months
|
The BPI-SF was developed to measure both intensity or severity of pain and pain interference with daily life dimensions. It measures pain intensity via 4 questions, that is, "pain at its worst in the last 24 hours", "pain at its least in the last 24 hours", "pain on the average", and "pain you have right now". The BPI-SF assesses how much pain has interfered with the following 7 activities: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Higher score indicates more pain. |
Baseline up to approximately 4 years 5 months
|
|
Change from Baseline in HRQoL as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Cancer Module (EORTC QLQ-C30) Scale Score
Aikaikkuna: Baseline up to approximately 4 years 5 months
|
The EORTC QLQ-C30 - Version 3 is a self-administered, 30-item questionnaire measuring the health-related quality of life of participants with cancer. EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), a global health status / quality of life scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent". A high score for a functional scale represents a high level of functioning, whereas a high score for a symptom scale/single item represents a high level of symptom. |
Baseline up to approximately 4 years 5 months
|
|
Change from Baseline in HRQoL as Assessed by EORTC Quality of Life Questionnaire-Prostate (EORTC QLQ-PR25) Scale Score
Aikaikkuna: Baseline up to approximately 4 years 5 months
|
The EORTC QLQ-PR25 is a self-completed instrument was specifically designed for prostate cancer patients and includes 25 items that cover 6 dimensions: (1) PR URI (urinary symptoms, 8 items), (2) PR BOW (bowel symptoms, 4 items), (3) PR HTR (hormonal treatment-related symptoms, 6 items), (4) PR AID (incontinence aid, 1 item), (5) PR SAC (sexually active, 2 items); and (6) PR SFU (sexual function, 4 items). Higher scores on symptom domains (for example., urinary, bowel, etc.) indicate greater symptom burden and higher scores on function domains (for example, Sexual Function) indicate better functioning. |
Baseline up to approximately 4 years 5 months
|
|
Change from Baseline in HRQoL as Assessed by European Quality of Life Visual Analog Scale (EQ-5D VAS) Score
Aikaikkuna: Baseline up to approximately 4 years 5 months
|
The EQ-5D descriptive system comprises 5 items across the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D includes a visual analog scale (EQ-VAS) that has endpoints labeled "best imaginable health state" and "worst imaginable health state" anchored at 100 and 0, respectively. Here, higher score indicates better quality of life. |
Baseline up to approximately 4 years 5 months
|
|
Time to Sustained Worsening of Pain as Assessed by BPI-SF
Aikaikkuna: Up to approximately 4 years 5 months
|
Time to sustained worsening of pain will be reported using BPI-SF. The BPI-SF was developed to measure both intensity or severity of pain and pain interference with daily life dimensions. It measures pain intensity via 4 questions, that is, "pain at its worst in the last 24 hours", "pain at its least in the last 24 hours", "pain on the average", and "pain you have right now". The BPI-SF assesses how much pain has interfered with the following 7 activities: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Higher score indicates more pain. |
Up to approximately 4 years 5 months
|
|
Treatment Side Effect as Assessed by EORTC IL46 Score
Aikaikkuna: Up to approximately 4 years 5 months
|
The EORTC IL46 is a single question that assesses bother (burden) of treatment. It is rated on a scale from 1 to 4, ranging from "not at all" to "very much". |
Up to approximately 4 years 5 months
|
|
European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) Scale Score
Aikaikkuna: Up to approximately 4 years 5 months
|
The EQ-5D descriptive system comprises 5 items across the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D-5L uses a 5-point Likert response scale ranging from "No problems" to "Extreme problems". Here, higher score indicates better quality of life. |
Up to approximately 4 years 5 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Urogenitaaliset sairaudet
- Sukuelinten sairaudet
- Sukuelinten kasvaimet, mies
- Urogenitaaliset kasvaimet
- Neoplasmat sivustoittain
- Neoplasmat
- Sukuelinten sairaudet, mies
- Eturauhasen sairaudet
- Miesten urogenitaaliset sairaudet
- Eturauhasen kasvaimet
- Kastraatioresistentit eturauhasen kasvaimet
- Orgaaniset kemikaalit
- Hiilivety
- Sykloparaffiinit
- Hiilivedyt, aliisykliset
- Hiilivedyt, sykliset
- Terpeenit
- Polisykliset yhdisteet
- Taksoidit
- Syklodekaanit
- Diterpeenit
- Raskaat
- Raskaat
- Steroidit
- Sulatettu rengasyhdisteet
- Raskaat
- Raskaat
- Doketakseli
- Prednisoni
- Prednisoloni
Muut tutkimustunnusnumerot
- 78278343PCR3003
- 2025-522713-29-00 (Rekisterin tunniste: EUCT number)
- 2025 (Yhdysvaltain NIH-apuraha/sopimus)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .